Goldman Sachs Group Inc Intercept Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$580 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 14, 2024	BUY	$9.99 - $18.71 $10.2 Million - $19.1 Million	1,019,073 New	1,019,073 $18.9 Million
Q3 2023 Nov 14, 2023	BUY	$9.99 - $18.71 $7.21 Million - $13.5 Million	721,653 Added 242.64%	1,019,073 $18.9 Million
Q2 2023 May 14, 2024	SELL	$9.17 - $19.29 $4.27 Million - $8.98 Million	-465,614 Reduced 61.02%	297,420 $3.29 Million
Q2 2023 Aug 14, 2023	SELL	$9.17 - $19.29 $4.27 Million - $8.98 Million	-465,614 Reduced 61.02%	297,420 $3.29 Million
Q1 2023 May 14, 2024	BUY	$12.53 - $21.71 $2.67 Million - $4.62 Million	212,795 Added 38.67%	763,034 $10.2 Million
Q1 2023 May 11, 2023	BUY	$12.53 - $21.71 $2.67 Million - $4.62 Million	212,795 Added 38.67%	763,034 $10.2 Million
Q4 2022 May 14, 2024	BUY	$11.61 - $16.11 $2.06 Million - $2.86 Million	177,773 Added 47.73%	550,239 $6.81 Million
Q4 2022 Feb 13, 2023	BUY	$11.61 - $16.11 $2.06 Million - $2.86 Million	177,773 Added 47.73%	550,239 $6.81 Million
Q3 2022 May 14, 2024	BUY	$12.21 - $19.7 $60,207 - $97,140	4,931 Added 1.34%	372,466 $5.2 Million
Q3 2022 Nov 10, 2022	BUY	$12.21 - $19.7 $60,207 - $97,140	4,931 Added 1.34%	372,466 $5.2 Million
Q2 2022 May 14, 2024	BUY	$11.23 - $19.59 $4.13 Million - $7.2 Million	367,535 New	367,535 $5.08 Million
Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $1.25 Million - $2.18 Million	-111,388 Reduced 23.26%	367,535 $5.08 Million
Q1 2022 May 16, 2022	BUY	$13.37 - $17.79 $601,061 - $799,767	44,956 Added 10.36%	478,923 $7.79 Million
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $1.93 Million - $2.65 Million	135,475 Added 45.39%	433,967 $7.07 Million
Q3 2021 Nov 10, 2021	BUY	$12.99 - $20.47 $3.88 Million - $6.11 Million	298,492 New	298,492 $4.43 Million

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account